• Ayşe Özkan, Mehmet Bülbül, Narin Derin, Osman Sinen, Güven Akçay, Hande Parlak, Mutay Aydın Aslan, and Aysel Ağar.
• Department of Physiology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
• Turk J Med Sci. 2021 Dec 13; 51 (6): 312631353126-3135.

Background/AimThe present study proposes to investigate the effect of neuropeptide–S (NPS) on cognitive functions and depression-like behavior of MPTP-induced experimental model of Parkinson’s disease (PD).Materials And MethodsThree-month-old C57BL/6 mice were randomly divided into three groups as; Control, Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and MPTP + NPS 0.1 nmol (received intraperitoneal injection of MPTP and intracerebroventricular injection of NPS, 0.1 nmol for seven days). The radial arm maze and pole tests were carried out, and the levels of tyrosine hydroxylase (TH) were determined using western blotting. A mass spectrometer was used to measure the levels of dopamine, glutamic acid, and glutamine.ResultsThe T-turn and time to descend enhanced in MPTP group, while these parameters were decreased by NPS treatment. In the MPTP group, the number of working memory errors (WME) and reference memory errors (RME) increased, whereas NPS administration decreased both parameters. Sucrose preference decreased in the MPTP group while increasing in the NPS group. MPTP injection significantly reduced dopamine, glutamic acid, and glutamine levels. NPS treatment restored the MPTP-induced reduction in glutamine and glutamic acid levels.ConclusionNPS may be involved in the future treatment of cognitive impairments and depression-like behaviors in PD.This work is licensed under a Creative Commons Attribution 4.0 International License.

26 keywords...

hide…